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The death receptor ligand TRAIL has shown remarkable promise as an anticancer agent. However, 
TRAIL signaling also activates NF-κB, which induces the antiapoptotic regulators Mcl-1 and cIAP2, 
thus compromising its efficacy. In this issue of Cancer Cell, El-Deiry and colleagues explore path-
ways that disrupt TRAIL-induced survival signaling and show that the Myc oncoprotein and the 
Raf kinase inhibitor Sorafenib sensitize otherwise TRAIL-resistant colon cancer cells by effectively 
reducing NF-κB-mediated transcription of Mcl-1. These findings suggest that combining TRAIL 
with agents that disrupt NF-κB regulation or binding or those that directly destabilize or disable 
Mcl-1 will have therapeutic benefit.In  designing  the  ideal  therapy  for 
cancer  treatment,  three  criteria  are 
highest on the  list. First,  the  therapy 
has  to  be  effective  in  killing  cancer 
cells  and  prevent  them  from  return-
ing. Second,  the  treatment needs  to 
be  selective  for  the  cancer  cell  and 
avoid  off-target  effects.  Indeed,  the 
untoward  side  effects  and  poor  tol-
erance  of  conventional  chemothera-
peutic agents are common pitfalls in 
the clinic. Finally, the ability to predict 
efficacy  based  on  biomarkers  per-
mits informed treatment, saving both 




of  chemorefractory  disease,  which 
ultimately kills the patient.
TRAIL  (TNF-α-related  apoptosis-
inducing  ligand)  has  attracted  a  lot 
of  interest  as  a  cancer  therapeutic 
agent.  TRAIL  is  trimeric  and  binds 
to  and  induces  trimerization  of  the 
death  receptors DR4  or DR5, which 
recruits  the  death-inducing  signal-
ing  complex  (DISC)  to  the  “death 
domains” present in the cytoplasmic 
region of these receptors. Formation 
of  the  DISC  induces  transcleavage 
and  activation  of  the  initiator  cas-
pase,  caspase  8.  At  this  point,  the 
signal  bifurcates with one  route  (the 
extrinsic pathway) leading to caspase 
8-mediated  activation  of  caspase 
3,  while  the  other  channels  through 
caspase  8  cleavage  of  Bid,  activat-
ing  the  intrinsic  cell  death  pathway 
and  amplifying  caspase  3  activation   Cancer Cell 12, July 2007 ©2007 Elsev(Figure 1A) (Takeda et al., 2007). Cells 
have been broadly delineated as type 
I,  in  which  the  extrinsic  pathway  is 
sufficient  to  trigger  cell  death,  and 
type  II,  which  require  amplification 
through the mitochondrion for apop-
tosis. In most tumor cells the latter is 
operational.  The  finding  that  TRAIL 
selectively  kills  cancer  cells  quickly 





discriminate  TRAIL-resistant  and  -
sensitive tumors, what the underlying 








8  activation,  by  interfering with Miz-
1-dependent  transcription  (Ricci  et 




complexity  to  the  mix.  As  a  model 





tosis.  Loss  of  Bax  cripples  TRAIL-
induced  death,  yet  Myc  sensitizes 
these cells  to TRAIL, which  is  rather 













TRAIL  induces  profound  increases 
in Mcl-1 and cIAP2  in Bax−/−, Bcl-XL-
overexpressing-Bax+/−,  or  caspase 
8/9  inhibitor-treated  Bax+/−  colon 
cancer  cells.  Further,  in Bax−/−  cells, 
TRAIL  also  provokes  the  disappear-
ance  of  Bak,  effectively  creating  a 
Bax/Bak-deficient cell that should be 
resistant  to  all  forms  of  death  (Wei 
et  al.,  2001),  which  obviously  is  not 
the  case.  Curiously,  Myc  does  not 
restore  Bak  expression  in  Bax-defi-
cient  TRAIL-treated  cells;  thus, Myc 
sensitization  seems  to  break  all  the 
rules  for  Bax/Bak  engagement—so 
what gives?
To explain it all, the authors turned 
to  the  inhibitory  effect  of  Myc  on 
TRAIL-induced  cIAP2  and  Mcl-1 
expression. Knockdown experiments 
demonstrated that Mcl-1 is really the 










insights  came  from  experi-
ments  implicating  NF-κB  in 
the Mcl-1 response to TRAIL—
here  Myc  binding  somehow 
blocks  the  activity  of  NF-κB 
when bound to its recognition 




a  cell  that  is  effectively  Bax/
Bak  null,  are  areas  of  impor-
tant investigation.
Obviously,  one  does  not 
want  to  overexpress  Myc  as 
a therapeutic strategy, yet the 
ability  of Myc  to  short  circuit 
NF-κB  in  the  TRAIL-to-Mcl-1 
pathway suggested other ave-
nues for intervention. El-Deiry 
and  colleagues  tested  the 
interesting hypothesis that sig-
naling  through  the  Ras  path-
way might represent an Achil-
les’  heel  one  could  exploit, 
and  here  the  authors  tested 





designed  to  target  Raf-1,  B-
Raf, and activated, mutant B-
Raf (a hallmark of melanomas 







et  al.,  2006;  Yu  et  al.,  2005). 











also  a  bit  fuzzy,  as Sorafenib 
blocks  binding  of  NF-κB  to Figure 1. Myc and the Raf Kinase Inhibitor Sorafenib 
Disable TRAIL-Directed Survival Pathways by Targeting 
the Intrinsic Apoptotic Machinery
(A) The binding of trimerized TRAIL ligand (red) to its cognate 




the  intrinsic cell death machinery  is  intact,  the proapoptotic 













leases the intrinsic pathway, and cell death ensues.Cancer Cell 12the  Mcl-1  promoter  without 
effecting  its  translocation  to 
the nucleus (Figure 1C). Again, 
the devil  is  in  the details, and 
sorting out how this really hap-
pens  is an  important  “to-do.” 
Experiments that evaluate the 
potential  effects  of  Sorafenib 
on  NF-κB  phosphorylation 
and/or  acetylation,  which  are 
important  for  its  transactiva-
tion functions, should be high 
on the list.
Since  a  major  conclusion 
of  Ricci  et  al.  (2007)  is  that 
the  “TRAIL”  leads  to  Mcl-1, 





colon  cancer  cells  initially 
declining and then rebounding 
to  markedly  increased  levels. 
Fluctuations  are  also  appar-
ent in Bax+/− cells treated with 
TRAIL  (i.e.,  this  pathway  is 




Mcl-1  turnover  or  translation 
may  also  be  in  the  mix,  and 
the roles of additional  regula-
tors  of Mcl-1  protein  such  as 
the  E3  ubiquitin  ligase  Mule 
and Noxa, which disrupts Mcl-




missing pieces  to  the  “disap-
pearing Bak” puzzle and could 
provide  additional  targets 
for  combination  therapy  with 
TRAIL.  Finally,  other  regula-
tors could also contribute. For 
example,  the  authors  show 
that  BH3-only  protein  Puma 
is  also  repressed  by  TRAIL 
in  Bax+/−  colon  cancer  cells, 
which may also be relevant.
So, does this new combina-
tion  of  TRAIL  and  Sorafenib 
represent  a  step  toward  the 
ideal  cancer  treatment?  Cer-







tion  therapy  has  been  successfully 
tried before, for example, using DNA-
damaging  agents.  But  the  elegant 
approach of  targeting the resistance 
pathway (upregulation of Mcl-1) using 
the  new  targeted  therapy  Sorafenib 
is  an  appealing  advance  and  opens 
avenues  for  combining  TRAIL  with 
small molecules or peptides that act 
directly on apoptotic sensitizers and 
effectors  (such  as  stabilized  BH3-
peptides targeting Mcl-1 and/or Bak) 
or other drugs that destabilize Mcl-1. 
However,  a  word  of  caution—sensi-
tizing  TRAIL-resistant  cancer  cells   Cancer Cell 12, July 2007 ©2007 Elsev
Lung  cancer  remains  the  leading 
cause  of  cancer  deaths  worldwide. 
While  the  disease  is  largely  refrac-
tory  to  conventional  chemotherapy, 
the  recent  emergence  of  selective 
tyrosine  kinase  inhibitors  (TKIs)  that 
elicit  dramatic  clinical  responses  in 
a  subset  of  treated  patients  repre-
sents  a  highly  promising  therapeu-










EGFR kinase inhibitors constitu
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However,  the  excitement  around 
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